Biliary drug excretion and stimulation of bile flow.
Explore the source record for details and available documents.
Administration, Oral↗
Biomedical subjects
Z Kopitar
Publications and source records attributed to Z Kopitar.
[Autoradiographic studies on the distribution of 14 C-labelled Bisolvon in the rat and mouse].
Explore the source record for details and available documents.
Aniline Compounds↗
[Specific binding of dipyridamol on human serum protein. Isolation, identification and characterization as alpha-1-acidic glycoprotein].
Explore the source record for details and available documents.
Blood Protein Electrophoresis↗
[Effect of serum proteins on the inhibition of adenosine permeability of human- and canine-erythrocyte membranes by 2,6-bis(diethanolamino)-4,8-dipiperidino-pyrimido-5,4-d-pyrimidine].
Explore the source record for details and available documents.
Animals↗
[Distribution of radioactivity in the organism and in exercretions of the rat after application of 14C-labelled 1-para-chlorophenyl-2,3-dimethyl-4--dimethylamino-butanol-2-HC1].
Explore the source record for details and available documents.
Amino Alcohols↗
Bioavailability of dihydroergosine in healthy volunteers.
Eight healthy volunteers received an oral dose of 10 mg and an intravenous dose of 0.75 mg of dihydroergosine. Plasma concentrations were measured by HPLC method, and some pharmacokinetic parameters were calculated. The biologic half-life in the elimination phase was 8.35 +/- 1.87 h after oral administration and 8.84 +/- 3.64 h after intravenous administration. In both cases of administration a secondary rise in plasma concentration of dihydroergosine was observed, which can be attributed to hepatic recycling. The calculated bioavailability of the drug was 9.80 +/- 2.8%.
Administration, Oral↗
The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine.
The effect of food and metoclopramide on the pharmacokinetics of bromocriptine was investigated in 7 healthy subjects. Plasma concentrations of bromocriptine were measured by radioimmunoassay after a single oral dose of 7.5 mg bromocriptine. Maximal plasma concentrations of bromocriptine were slightly lower when the drug was given after breakfast. Bioavailability of the drug was not significantly reduced by food nor by metoclopramide pre-treatment. Side effects of bromocriptine were considerably reduced by metoclopramide pre-treatment (0.5 mg/kg); the decrease was about 83% as estimated from Table II.
Administration, Oral↗
[Changes in plasma proteins and drug distribution in kidney and liver diseases].
Kidney and liver diseases induce alterations in drug binding to plasma proteins. These alterations are caused by qualitative and quantitative changes of plasma proteins and the presence of endogenous substances which act as competitive inhibitors of drug binding to plasma proteins. These changes are the most prominent in nephrotic syndrome and uremia among kidney diseases and in cirrhosis among liver diseases. The more important drugs in which the free fraction is changed in these entities are listed in the tables. The changes in drug distribution caused by plasma protein alterations may induce significant changes in entire drug pharmacokinetics. Discussed are theoretically expected and experimentally proven changes in plasma proteins in kidney and liver diseases and their influence to drug action and dosing regimen.
Blood Proteins↗